The U.S. Food and Drug Administration has approved the use of the triple-combo antiretroviral Complera (emtricitabine/rilpivirine/tenofovir) for HIV-positive adults who switch from a stable regimen—giving the drug a boost in its competition with other first-line therapies. Those who make the switch should have had at least six months of an undetectable viral load, never have experienced virologic failure and never have had resistance to the drugs included in Complera.